Esperion Therapeutics (ESPR) Reports Q3 Loss, Tops Revenue Estimates

Esperion Therapeutics (ESPR) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to a loss of $0.15 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -77.78%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $0.17 per share when it actually produced a loss of $0.02, delivering a surprise of +88.24%.Over the last four quarte ...